ad info

CNNin
 MAIN PAGE
 WORLD
 ASIANOW
 U.S.
 LOCAL
 POLITICS
 WEATHER
 BUSINESS
 SPORTS
 TECHNOLOGY
 NATURE
 ENTERTAINMENT
 BOOKS
 TRAVEL
 FOOD
 HEALTH
 AIDS
 Alternative
 Cancer
 Diet & Fitness
 Heart
 Men
 Seniors
 Women
 STYLE
 IN-DEPTH

 custom news
 Headline News brief
 daily almanac
 CNN networks
 CNN programs
 on-air transcripts
 news quiz

  CNN WEB SITES:
CNN Websites
 TIME INC. SITES:
 MORE SERVICES:
 video on demand
 video archive
 audio on demand
 news email services
 free email accounts
 desktop headlines
 pointcast
 pagenet

 DISCUSSION:
 message boards
 chat
 feedback

 SITE GUIDES:
 help
 contents
 search

 FASTER ACCESS:
 europe
 japan

 WEB SERVICES:
Health

FDA approves new device to clarify ambiguous mammogram results

gfx
 

April 19, 1999
Web posted at: 2:44 p.m. EDT (1844 GMT)

WASHINGTON (CNN) -- The U.S. Food and Drug Administration approved a new device Monday that will help determine whether a woman with an unclear mammography will need a biopsy.

The device, called the T-Scan 2000, is not intended for use in patients with clear mammographies or those who have not had mammographies. It specifically helps doctors by adding another step before moving from a questionable mammography to a biopsy.

The T-Scan 2000 is a hand-held scan probe placed on the breast to evaluate certain suspicious areas detected on the mammogram. The probe is connected to a computer, which displays an image of those areas of the breast.

The T-Scan images are based on impedance, which is a measure of how any material can affect the flow of electricity. The images are based on differences in the electrical flow between malignant tumor tissue and the surrounding normal tissue.

The device measures the impedance by passing a small electrical signal through the body and displaying on a computer the result from sensors in the probe contacting the breast. The computer image contains bright spots where the impedance is consistent with a possible malignancy.

"The device has the potential to reduce the number of negative biopsies, thus saving women worry about breast lesions that turn out to be non-cancerous," the FDA said. "It also has the potential to increase the identification of women who should be referred for early biopsy."

The device is manufactured by TransScan Medical Inc. of Ramsey, New Jersey.

As a condition of approval, the FDA said that TransScan will be required to conduct a post-market study on the effects of hormonal changes during the menstrual cycle on the device's ability to detect and distinguish among breast abnormalities.



RELATED STORY:
Studies show riskier breast cancer treatment no better than standard chemo
April 15, 1999

RELATED SITE:
Food and Drug Administration Home Page

ASCO: 1999 Plenary Session Abstracts Plus
Note: Pages will open in a new browser window
External sites are not endorsed by CNN Interactive.

LATEST HEALTH STORIES:
Affordable drug reduces mother-to-child HIV transmission, study says
A new risk factor for heart disease
The HMO debate: Who decides emergency care?
Tick-borne illness known to infect dogs found in humans
 LATEST HEADLINES:
SEARCH CNN.com
Enter keyword(s)   go    help

Back to the top   © 2001 Cable News Network. All Rights Reserved.
Terms under which this service is provided to you.
Read our privacy guidelines.